RT Journal Article SR Electronic T1 Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment JF Cancer Genomics - Proteomics JO Cancer Genomics Proteomics FD International Institute of Anticancer Research SP 531 OP 541 DO 10.21873/cgp.20155 VO 16 IS 6 A1 HELENA LINARDOU A1 VASSILIKI KOTOULA A1 GEORGE KOUVATSEAS A1 GIANNIS MOUNTZIOS A1 VASILIOS KARAVASILIS A1 EPAMINONDAS SAMANTAS A1 ANNA KALOGERA-FOUNTZILA A1 DESPINA TELEVANTOU A1 KYRIAKI PAPADOPOULOU A1 XANTHIPI MAVROPOULOU A1 EMILY DASKALAKI A1 THOMAS ZARAMBOUKAS A1 IOANNIS EFSTRATIOU A1 SOFIA LAMPAKI A1 GRIGORIOS RALLIS A1 ELENI RES A1 KONSTANTINOS N. SYRIGOS A1 PARIS A. KOSMIDIS A1 DIMITRIOS PECTASIDES A1 GEORGE FOUNTZILAS YR 2019 UL http://cgp.iiarjournals.org/content/16/6/531.abstract AB Background/Aim: KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC) and their prognostic role is unclear. We studied KRAS and EGFR genotyping in Greek NSCLC patients. Patients and Methods: KRAS and EGFR genotypes were centrally evaluated in 421 NSCLC patients (diagnosed September 1998 -June 2013) and associated with clinicopathological parameters. Outcome comparisons were performed in 288 patients receiving first line treatment. Results: Most patients were male (78.6%), >60 years old (63.9%), current smokers (51.1%), with adenocarcinoma histology (63.9%). EGFR and KRAS mutations were found in 10.7% and 16.6% of all histologies, respectively, and in 14.9% and 21.9% of adenocarcinomas. At 4.5 years median follow-up, KRAS status was an independent negative prognostic factor for overall survival (OS, p=0.016). KRAS mutations conferred 80% increased risk of death in patients receiving first-line treatment (p=0.002). Conclusion: The presence of KRAS mutations is an independent negative prognosticator among Greek NSCLC patients and an independent response predictor to first line treatment.